Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Genomics & Proteomics
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Cancer Genomics & Proteomics

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research Article
Open Access

Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis

IOANNIS PANAGOPOULOS, LUDMILA GORUNOVA, INGA MARIA RINVOLL JOHANNSDOTTIR, KRISTIN ANDERSEN, ARILD HOLTH, KLAUS BEISKE and SVERRE HEIM
Cancer Genomics & Proteomics January 2020, 17 (1) 41-48; DOI: https://doi.org/10.21873/cgp.20166
IOANNIS PANAGOPOULOS
1Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ioannis.panagopoulos@rr-research.no
LUDMILA GORUNOVA
1Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
INGA MARIA RINVOLL JOHANNSDOTTIR
2Department of Pediatric Cancer and Blood Disorders, Oslo University Hospital, Oslo, Norway
3National Advisory Unit on Late Effects after Cancer Treatment, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KRISTIN ANDERSEN
1Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ARILD HOLTH
4Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KLAUS BEISKE
4Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
5Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SVERRE HEIM
1Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
5Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: The chromosome translocation t(14;21)(q11;q22) was reported in four pediatric T-cell lymphoblastic leukemias and was shown to activate the OLIG2 gene. Materials and Methods: A pediatric T-cell lymphoblastic lymphoma was investigated using G-banding chromosome analysis, fluorescence in situ hybridization (FISH), and immunocytochemistry. Results: The malignant cells carried a t(14;21)(q11;q22) aberration. The translocation moves the enhancer elements of TRA/TRD from band 14q11 to 21q22, a few thousands kbp downstream of OLIG1 and OLIG2, resulting in the production of both OLIG1 and OLIG2 proteins. Conclusion: The translocation t(14;21)(q11;q22) occurs in some pediatric T-cell lymphoblastic malignancies. Activation of both OLIG1 and OLIG2 by t(14;21)(q11;q22) in T-lymphoblasts and the ensuing deregulation of thousands of genes could explain the highly malignant disease and resistance to treatment that has characterized this small group of patients.

  • Pediatric T-cell lymphoblastic lymphoma
  • chromosome translocation t(14;21)(q11;q22)
  • TRA/TRD enhancer
  • OLIG1 expression
  • OLIG2 expression
  • unfavorable prognosis

T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphomas (T-LBL) are malignant diseases in which early T-cell precursors proliferate and replace the normal hematopoietic cells. Although there is a difference between them with regards to gene expression profiles (1-3), the two diseases are considered to be aspects of the same malignancy and distinguished only by the degree of blast cell infiltration in the bone marrow (4-6). Bone marrow blast cell infiltration higher than 25% defines T-ALL whereas less than 25% infiltration defines T-LBL (2, 4, 5). Thus, in T-LBL, the abnormal lymphocytes are found in the lymph nodes or thymus whereas in T-ALL, the abnormal lymphocytes are seen mainly in the blood and bone marrow.

T-ALL and T-LBL patients carry in their malignant cells acquired genetic changes that contribute to increased proliferation, prolonged survival, and/or impaired differentiation of lymphoid hematopoietic progenitors (7-11). Many of the changes are in the form of non-random numerical or structural chromosome aberrations that can be detected microscopically and often carry prognostic significance (8).

We herein present a T-cell lymphoblastic lymphoma with the chromosome aberration t(14;21)(q11;q22), review the relevant literature, and conclude that the translocation probably carries an adverse prognosis.

Materials and Methods

Ethics statement. The study was approved by the regional ethics committee (Regional komité for medisinsk forskningsetikk Sør-Øst, Norway, http://helseforskning.etikkom.no).

Case report and immunocytochemical studies. A 13-year-old boy was admitted with vena cava superior syndrome, night sweats, and pain below the right costal margin. Diagnostic work-up showed a large mediastinal tumor, pleural fluid that almost filled the whole right lung, and metastases in both kidneys as well as in the skin. T-lymphoblasts were found in the pleural fluid, bone marrow, and spinal fluid (Figure 1A-D). Cytogenetic analysis revealed a translocation t(14;21) in T-cells from a mediastinal tumor biopsy and from the pleural fluid. The final diagnosis was T-cell non-Hodgkin's lymphoma. Because of the genetic findings (see below), immunocytochemistry was performed using OLIG1 and OLIG2 antibodies (Figure 1E and F). The OLIG1 antibody was a mouse monoclonal antibody (OLIG1 Monoclonal antibody 257219) purchased from Thermo Fisher Scientific (Waltham, Massachusetts, United States; Catalogue number MA5-23954) and applied at 1:400 dilution. For visualization, the Dako EnVision Flex + System (K8012; Dako, Glostrup, Denmark) was used as previously described (12). The OLIG2 antibody was a polyclonal goat antibody purchased from R&D Systems (Catalog number AF2418) and applied at 1:50 dilution. The Roche Ventana BenchMark ULTRA instrument was used. The section was pretreated with Cell Conditioning Solution (CC1) and detected using the OptiView DAB system.

The patient started on the EURO-LB-02 lymphoma protocol (13) but developed a large sinus venous thrombosis. Evaluation after 2 weeks of treatment showed some reduction of disease load, but after 4 weeks the tumor had again increased in size. Treatment was then switched to the NOPHO ALL 2008 high-risk protocol with intensive block treatment (14). No response after the first block (cyclophosphamide/etoposide) was seen, but there was good response after the second block (high dose methotrexate/high dose cytarabin). Before onset of the third block, however, the tumor again increased in volume. The patient received Nelarabin for five days with no effect on tumor and, during the following week, the blast count increased rapidly in the blood. The patient died peacefully in his sleep 4 months after diagnosis.

G-banding analysis. Cells from bone marrow, lymph node, and pleural effusion were cultured and harvested using standard techniques (15, 16). Chromosome preparations were G-banded with Leishman stain and examined (Figure 2). The karyotype was written according to The International System for Human Cytogenomic Nomenclature (ISCN) 2016 guidelines (17).

Fluorescence in situ hybridization (FISH). FISH analyses were performed on metaphase spreads and interphase nuclei using a commercial break apart probe (Cytocell) for the T cell receptor alpha/delta locus on chromosome band 14q11 (TRA/TRD) and a home-made break apart probe for chromosome band 21q22 (Figures 3 and 4). The BAC probes were purchased from the BACPAC Resource Center located at the Children's Hospital Oakland Research Institute (Oakland, CA) (https://bacpacresources.org/). Selection of BAC probes was based on the published (18) genomic breakpoint on der(21) (see below).

The BAC clones used were RP11-79D9 (proximal part of the probe, containing both the OLIG1 and OLIG2 genes, Position: chr21:32910480-33075022, GRCh38/hg38 assembly) and RP11-996D17 (distal part of the probe, Position: chr21:33281951-33446033). DNA was extracted whereupon the RP11-79D9 and RP1-995D17 probes were labelled with Fluorescein-12-dCTP (PerkinElmer, Boston, MA, USA) and Texas Red-5-dCTP (PerkinElmer) in order to obtain green and red signals, respectively, using the Abbott's nick translation kit (Des Plaines, IL, USA), and hybridized according to Abbott Molecular recommendations (http://www.abbottmolecular.com/home.html). Chromosome preparations were counterstained with 0.2 μg/ml DAPI and overlaid with a 24 x 50 mm2 coverslip. Fluorescent signals were captured and analyzed using the CytoVision system (Leica Biosystems, Newcastle, UK).

Sequence analysis. The BLAT alignment tool and the human genome browser at UCSC (19, 20) were used to map on the Human GRCh38/hg38 assembly the previously published (18) nucleotide sequence resulting from the t(14;21)(q11;q22).

Results

Cytogenetics. G-banding analysis of bone marrow cells yielded a normal karyotype (46,XY), whereas the analysis of lymph node cells showed 46,XY,t(14;21)(q11;q22)[3], and pleura effusion cells had the karyotype 46,XY,t(14;21)(q11;q22) [17]/46,XY,idem,del(6)(q13q23)[3] (Figure 2).

FISH. FISH with the TRA/TRD break apart probe showed that the TRA/TRD locus (14q11) had been rearranged and that the distal part of the probe had moved to the 21q22 band (green signal in Figure 3B and C). FISH with the 21q22 break apart probe showed that the distal part of the probe with BAC RP11-996D17 (red signal in Figure 4B and C) had moved to 14q11 whereas the proximal part with BAC RP11-79D9 and containing both the OLIG1 and OLIG2 genes, hybridized to the der(21)(q22) (green signal in Figure 4B and C) .

Immunocytochemistry. Immunostaining experiments with OLIG1 and OLIG2 antibodies showed that both proteins were produced in the T-cells (Figure 1E and F).

Sequence analysis. The sequence of the genomic breakpoint on der(21) reported by Wang et al. (18) was: AGGTGTTCAGTGCCTTGCGCGCGTGGCTGTCG-GGGATAGCAACTATAAACTGACATTTGG. Using the BLAT alignment tool, we mapped this sequence on the Human GRCh38/hg38 assembly and found that the breakpoint occurred at position Chr21:33110158 (AGGTGTTCAGTGCCTTGCGCGCGTGGCTGTCG: position chr21:33,110,127-33,110,158 and GGGATAGCAACTATAAACTGACATTTGG position chr14:22,483, 012-22,483,040). Our mapping of the above-mentioned sequence showed that the 3’-end of TRA/TRD, including the gene's enhancer, was placed distal to both the OLIG1 and OLIG2 genes which are transcribed from centromere to telomere. The genetic distance from the breakpoint to OLIG1 is 40 kbp, the genetic distance from the breakpoint to OLIG2 is 82 kbp, and hence the distance between OLIG1 and OLIG2 is 42 kbp.

Discussion

Including the present case, the cytogenetic aberration t(14;21)(q11;q22) has now been reported in five patients (18, 21-23). The four previously described patients had ALL whereas the present case was a T-LBL. Four of the patients were children aged 7, 8, 13, and 13 years whereas the fifth was a 50-week-old infant (Table I). Four patients died of their disease (including our case) whilst one was reported as being in relapse. Thus, although information is limited, the chromosome translocation t(14;21)(q11;q22) seems to occur in children with T-cell lymphoblastic malignancies, mostly in boys (male-to-female ratio is 4:1 so far), and may signify an adverse prognosis.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Microscopic examination of the T-cell lymphoblastic lymphoma. A: H&E stained image, magnification: ×60. B: Immunocytochemical staining with anti-CD3, magnification: ×60. C: Immunocytochemical staining with anti-CD1a, magnification: ×60. D: Immunocytochemical staining with anti-CD10, magnification: ×60. E: Immunocytochemical staining with anti-OLIG1, magnification ×60. F: Immunocytochemical staining with anti-OLIG2, magnification: ×60.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

G-banding analysis of cells from a lymph node showing the 46,XY,t(14;21)(q11;q22) chromosome translocation. Breakpoint positions are indicated by arrows.

In the first report of t(14;21)(q11;q22), cloning of the translocation breakpoint showed rearrangement of TRA/TRD in 14q11, identified OLIG2 in 21q22 (it was originally named BHLHB1), and showed that the latter gene was activated by the translocation (18). In the present study, we mapped the sequence of the genomic breakpoint on der(21) reported by Wang et al. (18) and found that the 3’-end of TRA/TRD, including the enhancer, was placed distal to both the OLIG1 and OLIG2 genes. We therefore estimated that, although only the OLIG2 gene was discovered and studied by Wang et al. (18), the result of t(14;21)(q11;q22) in their case probably was activation of both OLIG1 and OLIG2. FISH investigation of our case with a 21q22 break apart probe (Figure 4) indicated that the breakpoint was in the same region as that reported by Wang et al. (18). Furthermore, immunostaining experiments showed that both OLIG1 and OLIG2 proteins were produced by the T-cells (Figure 1E and F). Thus, the main molecular consequence of t(14;21)(q11;q22) is the relocation of enhancer elements of TRA/TRD from band 14q11 to 21q22, a few thousand kbp downstream of the OLIG1 gene, resulting in activation of both the OLIG1 and OLIG2 genes leading to the production of OLIG1 and OLIG2 proteins (Figure 1E and F).

The proteins OLIG1, OLIG2, and OLIG3 form the OLIG sub-family of transcription factors within the larger family of basic helix-loop-helix (bHLH) transcription factors (24). The OLIG1 and OLIG2 genes are expressed exclusively within the central nervous system where they play an important role in the development of motor neurons, oligodendrocytes, and a subset of astrocytes and ependymal cells (25-28). OLIG3 maps on chromosome band 6q23 and, at least in mice, plays a role in the development of class A and B neurons of the dorsal horn of the spinal cord (29). Expression profiling in mice models has shown that OLIG1 and OLIG2 regulate thousands of genes (24): 2,570 were up-regulated whereas 2,654 genes were down-regulated specifically in Olig2-/- mice, 2265 genes were up-regulated and 2,096 genes were down-regulated specifically in Olig1-/- mice, and there were also 1,383 commonly upregulated genes and 1491 commonly downregulated genes found in both Olig2-/- and Olig1-/- mice (24).

The OLIG2 gene has been shown to be involved in the development of brain cancers and can be used as a molecular marker for diffuse gliomas (30-32). Expression of OLIG2 was also reported in leukemia cell lines as well as breast cancer, melanoma, and non-small cell lung carcinoma cell lines (33). In the same study, the authors concluded that expression of OLIG2 in thymocytes was only weakly oncogenic and required collaborative events such as overexpression of LMO1, NOTCH1 or other cell proliferation signals in order to induce a highly penetrant leukemia (33). Recently, OLIG2 was found to be epigenetically regulated via DNA methylation in acute myeloid leukemia and expressed in two patients carrying the translocation t(15;17)/PML-RARA (34). Furthermore, stable overexpression of OLIG2 in non-expressing cell lines Kasumi-1 (a leukemic cell line with a t(8;21)(q22;q22) translocation resulting in the RUNX1-RUNX1T1 fusion gene) and U-937 (a histiocytic lymphoma cell line with a t(10;11)(p14;q23) translocation resulting in the CALM-AF10 fusion gene), using a lentiviral vector system, led to moderate growth inhibition after 4 days and resulted in signs of differentiation in U-937 cells (34). The authors concluded that OLIG2 may exert anti-proliferative activity in leukemia cell lines. The two studies mentioned above indicate that the expression of OLIG2 is not sufficient for the development of malignancy; additional genetic/expression events may be required.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

FISH analysis of cells from a lymph node using a commercial TCR alpha/delta locus (TRA/TRD) break apart probe. A: Ideogram of chromosome 14 showing the mapping of TRA/TRD on chromosome band 14q11.2 (red box). B: Diagram showing the proximal (red) and distal (green) parts of the TRA/TRD break apart probe. Additional genes in this region are also shown. Arrow indicates the genomic breakpoint (BP) reported by Wang et al. (18). The reported sequence around the BP is also given. C: Metaphase spread showing splitting of the TRA/TRD probe. The distal part (green label) of the probe hybridized to der(21) whereas the proximal part (red label) hybridized to der(14). Both distal and proximal parts hybridized to normal chromosome 14.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

The published lymphoblastic malignancies carrying the chromosome translocation t(14;21)(q11;q22).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

FISH analysis of cells from a lymph node using an OLIG2/OLIG1 break apart probe which was made from commercially available BACs. A: Ideogram of chromosome 21 showing the mapping of OLIG2/OLIG1 on chromosome band 21q22.1 (red box). B: Diagram showing the proximal (BAC RP11-79D9, green) and the distal (BAC RP11-996D17, red) parts of the OLIG2/OLIG1 break apart probe. Additional genes in this region are also shown. Arrow indicates the genomic breakpoint (BP) reported by Wang et al (18). The reported sequence around the BP is also given. C: Metaphase spread showing splitting of OLIG2/OLIG1 probe. The distal part (red label) of the probe hybridized to der(14) whereas the proximal part (green label) hybridized to der(21). Both distal and proximal parts hybridized to normal chromosome 21.

We conclude that activation of both OLIG1 and OLIG2 is of the essence in T-cell acute lymphoblastic leukemia/lymphoma brought about by the translocation t(14;21)(q11;q22). Deregulation of a plethora of genes by the proteins OLIG1 and OLIG2 may be the key to the highly malignant disease profile characteristic of these lymphoid malignancies.

Acknowledgements

This work was supported by grants from Radiumhospitalets Legater.

Footnotes

  • Authors' Contributions

    IP conceived the study, designed the experiments, evaluated the data, and drafted the manuscript. LG performed cytogenetic analysis and evaluated the FISH data. IMRJ made clinical evaluations and treated the patient. KA performed cytogenetic and FISH experiments and evaluated the data. AH performed immunocytochemistry examinations. KB performed pathological examination and evaluated immunocytochemical staining. SH assisted with experimental design and writing of the manuscript. All authors read and approved of the final manuscript.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors declare that they have no potential conflicts of interest.

  • Received October 27, 2019.
  • Revision received November 11, 2019.
  • Accepted November 15, 2019.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Raetz EA,
    2. Perkins SL,
    3. Bhojwani D,
    4. Smock K,
    5. Philip M,
    6. Carroll WL,
    7. Min DJ
    : Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 47: 130-140, 2006. PMID: 16358311. DOI: 10.1002/pbc.20550
    OpenUrlCrossRefPubMed
  2. ↵
    1. Hoelzer D,
    2. Gokbuget N
    : T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma 9 Suppl 3: S214-221, 2009. PMID: 19778844. DOI: 10.3816/CLM.2009.s.015
    OpenUrlCrossRefPubMed
  3. ↵
    1. Basso K,
    2. Mussolin L,
    3. Lettieri A,
    4. Brahmachary M,
    5. Lim WK,
    6. Califano A,
    7. Basso G,
    8. Biondi A,
    9. Cazzaniga G,
    10. Rosolen A
    : T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Cancer 50: 1063-1075, 2011. PMID: 21987448. DOI: 10.1002/gcc.20924
    OpenUrlCrossRefPubMed
  4. ↵
    1. Schmidt E,
    2. Burkhardt B
    : Lymphoblastic lymphoma in childhood and adolescence. Pediatr Hematol Oncol 30: 484-508, 2013. PMID: 23621872. DOI: 10.3109/08880018.2013.789574
    OpenUrl
  5. ↵
    1. Bassan R,
    2. Maino E,
    3. Cortelazzo S
    : Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol 96: 447-460, 2016. PMID: 26679753. DOI: 10.1111/ejh.12722
    OpenUrl
  6. ↵
    1. Cortelazzo S,
    2. Ferreri A,
    3. Hoelzer D,
    4. Ponzoni M
    : Lymphoblastic lymphoma. Crit Rev Oncol Hematol 113: 304-317, 2017. PMID: 28427520. DOI: 10.1016/j.critrevonc.2017.03.020
    OpenUrl
  7. ↵
    1. Bonn BR,
    2. Rohde M,
    3. Zimmermann M,
    4. Krieger D,
    5. Oschlies I,
    6. Niggli F,
    7. Wrobel G,
    8. Attarbaschi A,
    9. Escherich G,
    10. Klapper W,
    11. Reiter A,
    12. Burkhardt B
    : Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood 121: 3153-3160, 2013. PMID: 23396305. DOI: 10.1182/blood-2012-12-474148
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Heim S,
    2. Mitelman F
    : Cancer Cytogenetics: Chromosomal and Molecular Genetic Abberations of Tumor Cells: Wiley-Blackwell, 2015.
    1. Belver L,
    2. Ferrando A
    : The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer 16: 494-507, 2016. PMID: 27451956. DOI: 10.1038/nrc.2016.63
    OpenUrlCrossRefPubMed
    1. Girardi T,
    2. Vicente C,
    3. Cools J,
    4. De Keersmaecker K
    : The genetics and molecular biology of T-ALL. Blood 129: 1113-1123, 2017. PMID: 28115373. DOI: 10.1182/blood-2016-10-706465
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Sekimizu M,
    2. Sunami S,
    3. Nakazawa A,
    4. Hayashi Y,
    5. Okimoto Y,
    6. Saito AM,
    7. Horibe K,
    8. Tsurusawa M,
    9. Mori T
    : Chromosome abnormalities in advanced stage T-cell lymphoblastic lymphoma of children and adolescents: a report from Japanese Paediatric Leukaemia/Lymphoma Study Group (JPLSG) and review of the literature. Br J Haematol 154: 612-617, 2011. PMID: 21689091. DOI: 10.1111/j.1365-2141.2011.08788.x
    OpenUrlPubMed
  10. ↵
    1. Brunetti M,
    2. Holth A,
    3. Panagopoulos I,
    4. Staff AC,
    5. Micci F,
    6. Davidson B
    : Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma. Virchows Arch 474: 177-185, 2019. PMID: 30467600. DOI: 10.1007/s00428-018-2487-x
    OpenUrl
  11. ↵
    1. Landmann E,
    2. Burkhardt B,
    3. Zimmermann M,
    4. Meyer U,
    5. Woessmann W,
    6. Klapper W,
    7. Wrobel G,
    8. Rosolen A,
    9. Pillon M,
    10. Escherich G,
    11. Attarbaschi A,
    12. Beishuizen A,
    13. Mellgren K,
    14. Wynn R,
    15. Ratei R,
    16. Plesa A,
    17. Schrappe M,
    18. Reiter A,
    19. Bergeron C,
    20. Patte C,
    21. Bertrand Y
    : Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica 102: 2086-2096, 2017. PMID: 28983060. DOI: 10.3324/haematol.2015.139162
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Toft N,
    2. Birgens H,
    3. Abrahamsson J,
    4. Griskevicius L,
    5. Hallbook H,
    6. Heyman M,
    7. Klausen TW,
    8. Jonsson OG,
    9. Palk K,
    10. Pruunsild K,
    11. Quist-Paulsen P,
    12. Vaitkeviciene G,
    13. Vettenranta K,
    14. Asberg A,
    15. Frandsen TL,
    16. Marquart HV,
    17. Madsen HO,
    18. Noren-Nystrom U,
    19. Schmiegelow K
    : Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia 32: 606-615, 2018. PMID: 28819280. DOI: 10.1038/leu.2017.265
    OpenUrl
  13. ↵
    1. Rooney DE
    1. Czepulkowski B
    : Basic techniques for the preparation and analysis of chromosomes from bone marrow and leukaemic blood. In: Human cytogenetics: malignancy and acquired abnormalities (Rooney DE ed.). New York: Oxford University Press, pp. 1-26, 2001.
  14. ↵
    1. Rooney DE
    1. Harrison CJ
    : The lymphomas and chronic lymphoid leukaemias. In: Human cytogenetics: malignancy and acquired abnormalities (Rooney DE ed.). New York: Oxford University Press, pp. 87-110, 2001.
  15. ↵
    1. McGowan-Jordan J,
    2. Simons A,
    3. Schmid M
    : ISCN 2016: An International System for Human Cytogenomic Nomenclature. Basel: Karger, 2016.
  16. ↵
    1. Wang J,
    2. Jani-Sait SN,
    3. Escalon EA,
    4. Carroll AJ,
    5. de Jong PJ,
    6. Kirsch IR,
    7. Aplan PD
    : The t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell acute lymphoblastic leukemia activates the BHLHB1 gene. Proc Natl Acad Sci USA 97: 3497-3502, 2000. PMID: 10737801. DOI: 10.1073/pnas.97.7.3497
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Kent WJ
    : BLAT—the BLAST-like alignment tool. Genome Res 12: 656-664, 2002. PMID: 11932250. DOI: 10.1101/gr.229202
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Kent WJ,
    2. Sugnet CW,
    3. Furey TS,
    4. Roskin KM,
    5. Pringle TH,
    6. Zahler AM,
    7. Haussler D
    : The human genome browser at UCSC. Genome Res 12: 996-1006, 2002. PMID: 12045153. DOI: 10.1101/gr.229102
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Chessells JM,
    2. Harrison CJ,
    3. Kempski H,
    4. Webb DK,
    5. Wheatley K,
    6. Hann IM,
    7. Stevens RF,
    8. Harrison G,
    9. Gibson BE,
    10. party MRCCLw
    : Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 16: 776-784, 2002. PMID: 11986937. DOI: 10.1038/sj.leu.2402468
    OpenUrlCrossRefPubMed
    1. Jeandidier E,
    2. Dastugue N,
    3. Mugneret F,
    4. Lafage-Pochitaloff M,
    5. Mozziconacci MJ,
    6. Herens C,
    7. Michaux L,
    8. Verellen-Dumoulin C,
    9. Talmant P,
    10. Cornillet-Lefebvre P,
    11. Luquet I,
    12. Charrin C,
    13. Barin C,
    14. Collonge-Rame MA,
    15. Perot C,
    16. Van den Akker J,
    17. Gregoire MJ,
    18. Jonveaux P,
    19. Baranger L,
    20. Eclache-Saudreau V,
    21. Pages MP,
    22. Cabrol C,
    23. Terre C,
    24. Berger R,
    25. Groupe Francais de Cytogenetique H
    : Abnormalities of the long arm of chromosome 21 in 107 patients with hematopoietic disorders: a collaborative retrospective study of the Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet 166: 1-11, 2006. PMID: 16616106. DOI: 10.1016/j.cancergencyto.2005.08.005
    OpenUrlCrossRefPubMed
  20. ↵
    1. Chebihi ZT,
    2. Belkhayat A,
    3. Chadli E,
    4. Hessissen L,
    5. El Khorassani M,
    6. El Kababri M,
    7. Kili A,
    8. Khattab M,
    9. Bakri Y,
    10. Dakka N
    : The rare translocation t(14;21)(q11;q22) detected in a Moroccan patient with T-cell acute lymphoblastic leukemia. Leuk Res Rep 11: 1-4, 2019. PMID: 30533380. DOI: 10.1016/j.lrr.2018.11.001
    OpenUrl
  21. ↵
    1. Meijer DH,
    2. Kane MF,
    3. Mehta S,
    4. Liu H,
    5. Harrington E,
    6. Taylor CM,
    7. Stiles CD,
    8. Rowitch DH
    : Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2. Nat Rev Neurosci 13: 819-831, 2012. PMID: 23165259. DOI: 10.1038/nrn3386
    OpenUrlCrossRefPubMed
  22. ↵
    1. Lu QR,
    2. Yuk D,
    3. Alberta JA,
    4. Zhu Z,
    5. Pawlitzky I,
    6. Chan J,
    7. McMahon AP,
    8. Stiles CD,
    9. Rowitch DH
    : Sonic hedgehog – regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system. Neuron 25: 317-329, 2000. PMID: 10719888. DOI: 10.1016/s0896-6273(00)80897-1
    OpenUrlCrossRefPubMed
    1. Takebayashi H,
    2. Yoshida S,
    3. Sugimori M,
    4. Kosako H,
    5. Kominami R,
    6. Nakafuku M,
    7. Nabeshima Y
    : Dynamic expression of basic helix-loop-helix Olig family members: implication of Olig2 in neuron and oligodendrocyte differentiation and identification of a new member, Olig3. Mech Dev 99: 143-148, 2000. PMID: 11091082. DOI: 10.1016/s0925-4773(00)00466-4
    OpenUrlCrossRefPubMed
    1. Zhou Q,
    2. Wang S,
    3. Anderson DJ
    : Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors. Neuron 25: 331-343, 2000. PMID: 10719889. DOI: 10.1016/s0896-6273(00)80898-3
    OpenUrlCrossRefPubMed
  23. ↵
    1. Masahira N,
    2. Takebayashi H,
    3. Ono K,
    4. Watanabe K,
    5. Ding L,
    6. Furusho M,
    7. Ogawa Y,
    8. Nabeshima Y,
    9. Alvarez-Buylla A,
    10. Shimizu K,
    11. Ikenaka K
    : Olig2-positive progenitors in the embryonic spinal cord give rise not only to motoneurons and oligodendrocytes, but also to a subset of astrocytes and ependymal cells. Dev Biol 293: 358-369, 2006. PMID: 16581057. DOI: 10.1016/j.ydbio.2006.02.029
    OpenUrlCrossRefPubMed
  24. ↵
    1. Müller T,
    2. Anlag K,
    3. Wildner H,
    4. Britsch S,
    5. Treier M,
    6. Birchmeier C
    : The bHLH factor Olig3 coordinates the specification of dorsal neurons in the spinal cord. Genes Dev 19: 733-743, 2005. PMID: 15769945. DOI: 10.1101/gad.326105
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Tsigelny IF,
    2. Kouznetsova VL,
    3. Lian N,
    4. Kesari S
    : Molecular mechanisms of OLIG2 transcription factor in brain cancer. Oncotarget 7: 53074-53101, 2016. PMID: 27447975. DOI: 10.18632/oncotarget.10628
    OpenUrl
    1. Lu QR,
    2. Park JK,
    3. Noll E,
    4. Chan JA,
    5. Alberta J,
    6. Yuk D,
    7. Alzamora MG,
    8. Louis DN,
    9. Stiles CD,
    10. Rowitch DH,
    11. Black PM
    : Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A 98: 10851-10856, 2001. PMID: 11526205. DOI: 10.1073/pnas.181340798
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Ligon KL,
    2. Alberta JA,
    3. Kho AT,
    4. Weiss J,
    5. Kwaan MR,
    6. Nutt CL,
    7. Louis DN,
    8. Stiles CD,
    9. Rowitch DH
    : The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 63: 499-509, 2004. PMID: 15198128. DOI: 10.1093/jnen/63.5.499
    OpenUrlCrossRefPubMed
  27. ↵
    1. Lin YW,
    2. Deveney R,
    3. Barbara M,
    4. Iscove NN,
    5. Nimer SD,
    6. Slape C,
    7. Aplan PD
    : OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1. Cancer Res 65: 7151-7158, 2005. PMID: 16103065. DOI: 10.1158/0008-5472.CAN-05-1400
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Yalcin A,
    2. Kovarbasic M,
    3. Wehrle J,
    4. Claus R,
    5. Becker H,
    6. Abdelkarim M,
    7. Gaidzik VI,
    8. Schmidts A,
    9. Wasch R,
    10. Pahl HL,
    11. Dohner K,
    12. Bullinger L,
    13. Duyster J,
    14. Lubbert M,
    15. Hackanson B
    : The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. Exp Hematol 55: 76-85 e73, 2017. PMID: 28760688. DOI: 10.1016/j.exphem.2017.07.009
    OpenUrl
PreviousNext
Back to top

In this issue

Cancer Genomics - Proteomics: 17 (1)
Cancer Genomics & Proteomics
Vol. 17, Issue 1
January-February 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cancer Genomics & Proteomics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis
(Your Name) has sent you a message from Cancer Genomics & Proteomics
(Your Name) thought you would like to see the Cancer Genomics & Proteomics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis
IOANNIS PANAGOPOULOS, LUDMILA GORUNOVA, INGA MARIA RINVOLL JOHANNSDOTTIR, KRISTIN ANDERSEN, ARILD HOLTH, KLAUS BEISKE, SVERRE HEIM
Cancer Genomics & Proteomics Jan 2020, 17 (1) 41-48; DOI: 10.21873/cgp.20166

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis
IOANNIS PANAGOPOULOS, LUDMILA GORUNOVA, INGA MARIA RINVOLL JOHANNSDOTTIR, KRISTIN ANDERSEN, ARILD HOLTH, KLAUS BEISKE, SVERRE HEIM
Cancer Genomics & Proteomics Jan 2020, 17 (1) 41-48; DOI: 10.21873/cgp.20166
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Keywords

  • Pediatric T-cell lymphoblastic lymphoma
  • chromosome translocation t(14;21)(q11;q22)
  • TRA/TRD enhancer
  • OLIG1 expression
  • OLIG2 expression
  • unfavorable prognosis
Cancer & Genome Proteomics

© 2023 Cancer Genomics & Proteomics

Powered by HighWire